Piscitelli S C, Flexner C, Minor J R, Polis M A, Masur H
Department of Pharmacy, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Clin Infect Dis. 1996 Oct;23(4):685-93. doi: 10.1093/clinids/23.4.685.
Patients with AIDS who are receiving optimal medical care, including combination therapy with antiretroviral agents and more effective prophylaxis and therapy for opportunistic infections and neoplasms, are surviving longer. However, the potential for drug interactions in these patients is increased because many of the currently used antibiotics and antiviral agents have profound effects on the hepatic cytochrome P-450 enzyme system, on renal tubular function, and on bone marrow function. In this AIDS Commentary, Dr. Piscitelli and colleagues have succinctly reviewed the current state of our knowledge regarding the potential for additive or synergistic drug interactions that can result in enhanced toxicity or, alternatively, augmented therapeutic benefit. Information on these interactions will become more important as more intensive and effective therapy becomes available for persons with far-advanced infection due to human immunodeficiency virus type 1.
接受最佳医疗护理的艾滋病患者，包括使用抗逆转录病毒药物进行联合治疗以及对机会性感染和肿瘤进行更有效的预防和治疗，生存期正在延长。然而，这些患者发生药物相互作用的可能性增加了，因为目前使用的许多抗生素和抗病毒药物对肝脏细胞色素P - 450酶系统、肾小管功能和骨髓功能都有深远影响。在这篇艾滋病评论中，皮斯西泰利博士及其同事简要回顾了我们目前对于可能导致毒性增强或治疗益处增加的相加或协同药物相互作用的认识现状。随着针对1型人类免疫缺陷病毒导致的晚期感染患者有了更强化和有效的治疗方法，关于这些相互作用的信息将变得更加重要。
